Parkinson’s disease brings on the shakes, and these tremors often get worse as the disease progresses. To prevent this symptom from interfering with patients’ daily lives, researchers in London have devised a clever arm exoskeleton that recognizes actions that require fine motor control, like lifting a cup or pointing, and turns on to suppress the tremors at those crucial moments.
Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced the availability of Xadago® (safinamide) in the United Kingdom.
When he was a 24-year-old medical student living in London, Faii Ong was assigned to care for a 103-year-old patient who suffered from Parkinson’s, the progressive neurological condition that affects a person’s ease of movement. After watching her struggle to eat a bowl of soup, Ong asked another nurse what more could be done to help the woman. “There’s nothing,” he was grimly told.
Fresh from its recent award as one of the 49 most innovative start-ups in the world by the World Economic Forum, Israeli biotechnology firm ElMindA, developers of the world’s first FDA-approved neural functional assessment tool to visualize serious brain trauma and illnesses, announced last week that it had received $28 million in a Series C financing round.
ElMindA had to turn away investors anxious to put their money into what could be the next big Israeli med tech exit, according to investment experts familiar with the firm.
El sistema está siendo probado con 50 pacientes de varios países y es capaz de actuar cuando la persona sufre dificultades en la marcha o bloqueo mediante estimuladores sensoriales auditivos y eléctricos.
NeuroDerm Ltd's shares more than doubled in value on Tuesday, after the company said data from a mid-stage study suggested that a higher dose of its Parkinson's drug could provide an alternative to treatments that require surgery.
The trial evaluated two liquid formulations of the drug, levodopa/carbidopa (LD/CD), in 16 patients with an advanced form of the disease to assess its capacity to reduce Parkinson's-related motor complications, the Israel-based company said.
Delivered through a belt-worn pump, the two versions of the drug, ND0612H and ND0612L, were compared with oral forms of LD/CD, the standard of care for Parkinson's.
For some time, doctors and neuroscientists have suggested that people with diabetes are more likely to develop neurodegenerative diseases than non-diabetic individuals, but were unable to prove their hypothesis. Now Israeli scientists at Israel’s Ben Gurion University in the Negev have found a definite link between Type II diabetes and the propensity for developing Parkinson’s disease.
Une étude menée par des chercheurs de l'Institut Max Planck de biologie moléculaire et cellulaire et de génétique de Dresde (Saxe) montre qu'un apport en enzymes D-lactate et glycolate pourrait freiner voir stopper la destruction de la substance noire [1].
